RhyGaze raised $86M in a Series A round led by GV to further develop a novel gene therapy for vision restoration.
Jan 10, 2025•11 months ago
Amount Raised
$86 Million
Round Type
series a
BaselBiotechnologyHealth CareInvestors
Novartis Venture FundBio Generation VenturesF Prime CapitalArch Venture PartnersGv
Description
RhyGaze secured a Series A financing of USD 86 million to advance its lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. The funding will support pharmacology and toxicology testing, observational studies, and a first-in-human clinical trial.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech